The data from the North American phase III SWOG S0033/CALGB 150105 study further confirmed the favorable impact of KIT exon 11 mutations when compared with KIT exon 9 mutations for the objective response rate (ORR) (71.7 vs. 44.4%; p = 0.007), median time to tumor progression (24.7 vs. 16.7 months; p = 0.0013), and median OS (60.0 vs. 38.4 months; p = 0.011).81 Here, KIT is linked to neoplasm.